SPRO (Spero Therapeutics) Growth Rank: 3 (As of Jul. 11, 2026) — 25% Below Median


SPRO Spero Therapeutics Inc SPRO
55 GF Score
Price $2.10
GF Value $1.05
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Spero Therapeutics Growth Rank?

Spero Therapeutics SPRO -0.94% 55 Growth Rank is 3 as of Jul. 11, 2026, which is 25% below its 10-year median of 4.00. GuruFocus rates SPRO with a GF Score™ of 55/100 and a GF Value™ of $1.05 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Spero Therapeutics has the Growth Rank of 3.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Spero Therapeutics Growth Rank Related Terms

SPRO vs VXRT, ADCT, GNLX: Growth Rank Comparison

For the Biotechnology subindustry, Spero Therapeutics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spero Therapeutics Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Growth Rank distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's Growth Rank falls into.


SPRO
55GF Score
Spero Therapeutics Inc SPRO
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 3 mean?
Spero Therapeutics (SPRO) has a Growth Rank of 3 as of Jul. 11, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Spero Therapeutics and its competitors. This is 25% below median its historical median of 4.00. Over the past decade, Spero Therapeutics' Growth Rank has ranged from 3.00 to 5.00.
Is Spero Therapeutics' Growth Rank too high?
Spero Therapeutics' current Growth Rank of 3 is 25% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 5.00. Overall, Spero Therapeutics has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spero Therapeutics' Growth Rank compare to VXRT and ADCT?
Spero Therapeutics' Growth Rank of 3 can be compared against companies in the Biotechnology industry. Historically, Spero Therapeutics' own Growth Rank has ranged from 3.00 to 5.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Spero Therapeutics and its competitors. Spero Therapeutics's current Growth Rank is 3, which is 25% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spero Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spero Therapeutics (SPRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.05, compared to a current price of $2.10 — trading 99.5% above its estimated fair value. The current Growth Rank is 3, which is 25% below median its 10-year median of 4.00. Spero Therapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Spero Therapeutics (SPRO), the current Growth Rank is 3 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spero Therapeutics (SPRO) Overvalued in 2026?

Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued. The current stock price of $2.10 is trading 99.5% above its estimated GF Value™ of $1.05. GuruFocus considers Spero Therapeutics to be Significantly Overvalued.

Key valuation signals for SPRO:

  • Growth Rank: 3 (25% below median its 10-year median of 4.00)
  • GF Value™: $1.05 vs. price of $2.10 (99.5% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spero Therapeutics Business Description

Other Exchanges 2HA:Germany
Address 675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
55GF Score

Get the complete analysis for SPRO

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.10
Price
$1.05
GF Value